Compare LFUS & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LFUS | APGE |
|---|---|---|
| Founded | 1927 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 10.2B |
| IPO Year | 1996 | 2023 |
| Metric | LFUS | APGE |
|---|---|---|
| Price | $417.64 | $135.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $366.67 | $109.67 |
| AVG Volume (30 Days) | 182.3K | ★ 1.3M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.96 | N/A |
| Revenue | ★ $757,853,000.00 | N/A |
| Revenue This Year | $14.65 | N/A |
| Revenue Next Year | $6.98 | N/A |
| P/E Ratio | $139.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $233.36 | $35.39 |
| 52 Week High | $500.57 | $135.09 |
| Indicator | LFUS | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 78.58 |
| Support Level | $386.67 | $134.03 |
| Resistance Level | $426.44 | N/A |
| Average True Range (ATR) | 15.42 | 0.10 |
| MACD | -1.89 | -0.39 |
| Stochastic Oscillator | 20.52 | 96.88 |
Littelfuse is a supplier of circuit protection products (such as fuses and relays) for the transportation, industrial, telecommunications, and consumer electronics end markets. Littelfuse also holds a minority power semiconductor business, primarily serving high-voltage industrial applications. Littelfuse sells globally across both distribution and direct channels, and organizes its business into the three segments of electronics, transportation, and industrial. Littelfuse is a serial acquirer of smaller, bolt-on adjacent firms.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.